Condition Directory

Hypertension clinical trials

Directory of U.S. ClinicalTrials.gov public records for Hypertension. Browse Hypertension recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3919

Shown on this page

Current sort

How Hypertension studies are organized in the registry

“Hypertension” searches also surface pulmonary hypertension — a different disease with its own research community — so watch for “pulmonary” in titles when scanning results. The blood-pressure portfolio itself includes a high share of behavioral, dietary, and device studies alongside medication trials.

Terms that often appear in related listings

blood pressure resistant hypertension pulmonary hypertension renal denervation

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1057–1068 of 3,919 matching trials for Hypertension.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Hypertension
Interventions: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Preeclampsia
Interventions: Salsalate Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Iowa City, Iowa • University Park, Pennsylvania

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Preeclampsia Severe, Pre-Eclampsia, Preeclampsia, Preeclampsia Second Trimester, Preeclampsia Complicating Childbirth, Preeclampsia Puerperium, Preterm
Interventions: Metformin, Esomeprazole; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Preeclampsia, Microvascular Function
Interventions: Acetylcholine, Endothelin-1; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Brain Injuries, Intracranial Pressure Increase, Monitoring
Interventions: Intracranial Pressure Noninvasive Monitoring; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pulmonary Hypertension, Metal Poison
Interventions: Metal level measurements; Diagnostic Test
Lead sponsor: Jiapeng Huang; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pulmonary Hypertension
Interventions: Frespaciguat, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Interventions: Frespaciguat, Placebo to Frespaciguat; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 22 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Kara Whitaker; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Iowa City, Iowa • Pittsburgh, Pennsylvania • Morgantown, West Virginia

Conditions: Hypertension
Interventions: CDS Alone, CDS plus practice facilitation; Other
Lead sponsor: New York City Department of Health and Mental Hygiene; Government
Eligibility: 18 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Queens, New York

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Atlanta, Georgia • Wichita, Kansas • Bloomington, Minnesota + 7 more

About this Hypertension clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Hypertension as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Hypertension.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Hypertension clinical trials

How Hypertension studies are organized in the registry

Filter and sort this condition

Live official records

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Metformin and Esomeprazole in Preterm Pre-eclampsia

Prenatal Aspirin and Postpartum Vascular Function

Correlation Between Noninvasive Blood Vessel Functionality Parameters and Cerebral Hemodynamics in Neurocritical Care Patients

Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

The Pregnancy 24/7 Cohort Study

Practice Facilitation to Scale up a CDS for Hypertension Management

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

About this Hypertension clinical trials directory page